This mechanism was confirmed in a pre-clinical study, which suggested that the application of anti-VEGF-A antibody (sunitinib) in CT26 tumor-bearing mice increased the infiltration of cytotoxic tumor-infiltrating lymphocytes (TIL) and decreased expression of PD-1 in CD8+T cells (36). This evidence concerns the gene VEGFA and neoplasm.